Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
Compensation Framework Study
First Interim Report
Second Interim Report
The Inquiry Report
Publication Day
Evidence
Evidence
Hearings Archive
Compensation
Support
Confidential Psychological Support
Interim Payments
Support Groups
Get in touch
Infected Blood Support Schemes
Treatment and aftercare
Medical Evidence
Expenses Guidance
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
After a child was admitted in 1981 following an accident where cryoprecipitate "failed to do the job that was asked of it on that occasion", Dr Dempsey's "confidence in cryoprecipitate" was shaken.
Published on:
30 September, 2024
In August 1980, cryoprecipitate was used "fairly exclusively" in the Royal Belfast Hospital for Sick Children haemophilia unit.
Published on:
30 September, 2024
Dr Dempsey stated that there were no separate annual returns for the royal Belfast Hospital for Sick Children. The returns were amalgamated with the adult haemophilia centre at the Royal Victoria Hospital and sent to Oxford "as a unified whole."
Published on:
30 September, 2024
In Belfast, children with bleeding disorders were treated at the Royal Belfast Hospital for Sick Children until around the age of 14. They were then transferred to the haemophilia centre at the Royal Victoria Hospital.
Published on:
30 September, 2024
According to Dr Dempsey, in regards non-A non-B Hepatitis, around 1980 there was a "general feeling" amongst clinicians that it was not a major concern, but there were patients who did have evidence of chronic liver disease.
Published on:
30 September, 2024
Dr Dempsey recalled that non-A non-B Hepatitis was not thought sufficiently serious to merit withdrawal of "the only really effective treatment for severe/moderate haemophilia" in reference to factor concentrate.
Published on:
30 September, 2024
Dr Dempsey understood there was still a risk of non-A non-B Hepatitis from commercial concentrates, but there was also a risk from NHS concentrates. He acknowledged that the risk with cryoprecipitate was "very much reduced risk."
Published on:
30 September, 2024
Dr Dempsey described batch dedication as "extremely difficult" and as something that ultimately did not work.
Published on:
30 September, 2024
Dr Dempsey had gathered from reading UKHCDO minutes that things had improved considerably in relation to the safety of commercial concentrates.
Published on:
30 September, 2024
Dr Dempsey recalled that the pharmaceutical firms, mostly Armour, were "keen to emphasise the fact that they'd tightened up on the type of donor they looked to for their plasma source" and reassured him that he was "disposed to look favourably on commercial concentrates at that point in time."
Published on:
02 October, 2024
Children at the RBHSC with moderate haemophilia were treated with these commercial concentrates; children with mild haemophilia were treated with DDAVP and tranexamic acid.
Published on:
02 October, 2024
Dr Dempsey's patients who would have been treated with commercial concentrates and SNBTS concentrates - were infected with Hepatitis C.
Published on:
02 October, 2024
Dr Dempsey was not aware, that BPL was producing a product at this time (8Y) which did not transmit hepatitis; had he known about it, he would have phoned BPL and requested a supply.
Published on:
02 October, 2024
Dr Dempsey continued to use SNBTS concentrates until he became aware of the infection of patients in Edinburgh. He used the heat-treated product NY until July 1987 when the next generation product Z8 became available. He was aware that non-A non-B Hepatitis could still be transmitted by NY.
Published on:
02 October, 2024
Dr Dempsey would not have used concentrate at all "given what was likely - or what was going to happen further down the road." The NHS product might have been a "better modality of treatment" to have employed back in 1981.
Published on:
02 October, 2024
Dr Winter told the Penrose Inquiry that by December 1982 it should have been clear to clinicians that AIDS was a disorder transmissible by blood and blood products and that it was "the only clinical interpretation of the data that was available."
Published on:
30 September, 2024
A paper titled "Acquired Immunodeficiency Syndrome: Infection and Neoplasia in Homosexual Men and Intravenous Drug Addicts" was presented to the Second International Symposium on Infections in the Immunocompromised Host. The paper named blood as a potential vehicle of AIDS infection.
Published on:
30 September, 2024
In his letter to The Lancet, Dr Jones recommended "continued, careful surveillance of the severely affected haemophilic population." Yet it made no mention of a virus as an infective agent.
Published on:
30 September, 2024
In a letter to the Press Council, Dr Jones lodged a formal complaint about an article on The Mail on Sunday with the headline "Hospitals using killer blood". He argued that there was no proof that a virus was the cause of AIDS nor that it was imported from the US.
Published on:
30 September, 2024
In a letter to colleagues, Dr Jones stressed that the link between AIDS and Haemophilia is weak and warned against withdrawing Factor 8 treatment.
Published on:
30 September, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2314
Page
2315
Page
2316
Page
2317
Current page
2318
Page
2319
Page
2320
Page
2321
Page
2322
…
Next page
Next
Last page
Last